In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

A Rapid and Effective Antidote for Anticoagulant Bleeds

Prevention


Rome, Italy – 30 August, 2016: A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.

Andexanet alfa reduced anticoagulant activity by roughly 90% within half an hour among patients with acute major bleeding while receiving a factor Xa (fXa) inhibitor, resulting in “excellent or good” haemostasis at 12 hours in most subjects, reported lead investigator Stuart J. Connolly, MD, from McMaster University, in Hamilton Ontario, Canada.

The ANdexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors (ANNEXA-4) study was presented at ESC Congress 2016, with simultaneous publication in The New England Journal of Medicine.

“Andexanet is the first specific agent designed for reversal of factor X inhibitors. Although it has been shown to reduce anti-fXa activity in volunteers, until now we did not have experience in acutely bleeding patients. In these patients andexanet reduced the anticoagulant effect of the factor Xa inhibitors and was associated with effective haemostasis in most patients,” according to Dr. Mark Crowther, ANNEXA-4 co-principal investigator, also from McMaster University.

The interim results include 67 patients, mean age 77 years, who required urgent reversal of acute major bleeding within 18 hours of receiving either a direct (apixaban, rivaroxaban, edoxaban) or indirect (enoxaparin) fXa inhibitor.

The primary site of bleeding was gastrointestinal 49% of patients, and intracranial in 42%.

For ethical reasons, the study was not randomised, and all patients received andexanet – first in an immediate bolus over 15-30 minutes, followed by a 2 hour infusion. Dosing was based on which fXa inhibitor they had been exposed to, and when.

Patients were assessed at baseline, end-of-bolus, and end of the 2-hour infusion, as well as at 4, 8, and 12 hours, and 3 and 30 days post-infusion.

Among 47 patients included in the efficacy assessment, there was an 89% decrease in anti-fXa activity from baseline to end-of-bolus for those exposed to rivaroxaban (n=26), and a corresponding 93% reduction for those exposed to apixaban (n=20).

At 12 hours, clinical hemostatic efficacy was rated as “good to excellent” in 79% of patients.

Thrombotic events occurred in 18% of subjects during 30 day follow up. “This rate of events is not unexpected considering the thrombotic potential of the patients and the fact that in most of them anticoagulation was discontinued at the time of bleeding and not restarted,” said Dr. Connolly.

“This preliminary report of the ongoing ANNEXA-4 study shows us that andexanet rapidly reverses anti-factor Xa activity in acutely bleeding patients and this is associated with excellent or good hemostasis in most.”

Ends

Notes to editor

Sources of funding: The study was funded by Portola Pharmaceuticals.

Disclosures: Both Dr. Connolly and Dr. Crowther have  received research support and fees for consulting and lecturing from Portola Pharmaceutical Co.

 

ESC Press Office
For background information, please contact the ESC Press Office at media@escardio.org.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575 

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148 

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

 

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org

 

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.